
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Regular serial screening by dermatologists may be the key to ensuring survival for patients at high risk of melanoma, according to a study. In the study, which is now in its 20th year, no melanoma deaths occurred in any higher-risk patients who underwent serial screening in the private practice of Ronald N. Shore, M.D.






